主动加温湿化无创通气与经鼻高流量氧疗预防肥胖患者再插管的随机临床试验
这项在西班牙两个ICU开展的随机对照试验纳入144例体重指数>30、再插管风险因素≤3个且准备计划拔管的成人患者,随机接受拔管后48小时主动加温湿化无创通气(72例)或经鼻高流量氧疗(72例)。主要结局为拔管后7天内再插管率,无创通气组17例(23.6%),经鼻高流量氧疗组24例(33.3%),组间差异9.7%(95%CI -4.9至24.4),未达统计学显著。所有次要分析均无显著差异;探索性贝叶斯分析显示无创通气降低再插管的概率分别为99%(数据驱动先验)、90%(最小信息先验)或89%(怀疑先验)。作者结论为两组再插管率无显著差异,但存在检验效能不足的风险。
要点
- 在中等风险肥胖成人ICU患者中,拔管后48小时主动加温湿化无创通气组7天内再插管17例(23.6%),经鼻高流量氧疗组24例(33.3%),差异9.7%(95%CI -4.9至24.4),未达统计学显著。
- 所有次要分析均显示无显著差异。
- 探索性贝叶斯分析中,无创通气降低再插管的概率为99%(数据驱动先验)、90%(最小信息先验)或89%(怀疑先验)。
- 纳入标准为体重指数>30、再插管风险因素≤3个且准备计划拔管,自主呼吸试验结束时存在高碳酸血症的患者被排除。
- 作者指出结果存在检验效能不足的风险。
适用人群与场景
- 西班牙两个ICU中准备计划拔管的成人患者,体重指数>30,再插管风险因素≤3个(中等风险)。
- 排除自主呼吸试验结束时存在高碳酸血症的患者。
诊断标准与关键阈值
- 纳入标准:体重指数>30,再插管风险因素≤3个,准备计划拔管。
- 排除标准:自主呼吸试验结束时存在高碳酸血症。
处置流程与药物剂量
- 拔管后随机接受主动加温湿化无创通气或经鼻高流量氧疗,持续48小时。
研究设计与关键结果
- 随机对照试验,西班牙两个ICU,2020年6月至2021年6月,纳入144例患者(中位年龄61岁,25th-75th百分位范围61-67岁;男性65例,45%),无创通气组72例,经鼻高流量氧疗组72例。
- 主要结局:拔管后7天内再插管率,无创通气组17例(23.6%) vs 经鼻高流量氧疗组24例(33.3%),组间差异9.7%(95%CI -4.9至24.4),未达统计学显著。
- 所有次要分析均显示无显著差异。
- 探索性贝叶斯分析:无创通气降低再插管的概率为99%(数据驱动先验)、90%(最小信息先验)或89%(怀疑先验)。
证据类型、等级与局限
- 证据类型:随机对照试验。
- 局限:作者指出存在检验效能不足的风险。
对床旁实践的改变
- 作者结论:在中等风险拔管失败的肥胖成人重症患者中,主动加温湿化无创通气较经鼻高流量氧疗未显著降低再插管率,但存在检验效能不足的风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Rationale: The optimal strategy to prevent reintubation in patients with obesity remains uncertain. Objectives: We aimed to determine whether noninvasive ventilation (NIV) with active humidification is superior to a high-flow nasal cannula (HFNC) in preventing reintubation in patients with obesity at intermediate risk. Methods: We conducted a randomized controlled trial in two ICUs in Spain (June 2020-June 2021). We included patients ready for planned extubation with a body mass index >30 and three or fewer risk factors for reintubation. Patients with hypercapnia at the end of the spontaneous breathing trial were excluded. Patients were randomized to undergo NIV with active humidification or HFNC for 48 hours after extubation. The primary outcome was the reintubation rate within 7 days after extubation. As a secondary analysis, we performed a post hoc Bayesian analysis using three different priors. Measurements and Main Results: Of 144 patients (median age, 61 [25th-75th percentile range, 61-67] yr; 65 [45%] men), 72 received NIV and 72 received an HFNC. Reintubation was required in 17 (23.6%) patients receiving NIV and in 24 (33.3%) patients receiving HFNC (difference between groups, 9.7; 95% confidence interval, -4.9, 24.4). All of the secondary analysis showed nonsignificant differences. In the exploratory Bayesian analysis, the probability of a reduction in reintubation with NIV was 99% (data-driven prior), 90% (minimally informative prior), or 89% (skeptical prior). Conclusions: Among adult critically ill patients with obesity at intermediate risk for extubation failure, the rate of reintubation was not significantly lower with NIV than with HFNC. Nevertheless, there is a risk for underpowered results. Clinical trial registered with www.clinicaltrials.gov (NCT04125342).
参考来源
- Hernández G, Dianti J, Paredes I, et al. Humidified Noninvasive Ventilation versus High-Flow Therapy to Prevent Reintubation in Patients with Obesity: A Randomized Clinical Trial. Am J Respir Crit Care Med. 2025. PMID: 39514845. doi:10.1164/rccm.202403-0523OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。